Synta Pharmaceuticals Corp. Share Price Nasdaq
Equities
US87162T2069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 75.76M 5.96B | Sales 2025 * | 361M 28.43B | Capitalization | 4.81B 378B |
---|---|---|---|---|---|
Net income 2024 * | -583M -45.9B | Net income 2025 * | -403M -31.73B | EV / Sales 2024 * | 54.3 x |
Net cash position 2024 * | 694M 54.61B | Net cash position 2025 * | 292M 22.97B | EV / Sales 2025 * | 12.5 x |
P/E ratio 2024 * |
-7.96
x | P/E ratio 2025 * |
-12.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.63% |
Latest transcript on Synta Pharmaceuticals Corp.
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 31/08/11 |
William Sibold
CEO | Chief Executive Officer | - | 07/09/23 |
Rebecca Taub
FOU | Founder | 71 | 30/06/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Craves
FOU | Founder | 78 | 31/08/11 |
Julian Baker
CHM | Chairman | 57 | 14/06/23 |
Ken Bate
BRD | Director/Board Member | 73 | 21/07/16 |
1st Jan change | Capi. | |
---|---|---|
+8.92% | 114B | |
+10.48% | 105B | |
-3.09% | 21.73B | |
-6.45% | 23.83B | |
-10.67% | 18.1B | |
-42.36% | 16.34B | |
-14.45% | 16.13B | |
+3.76% | 13.75B | |
+28.94% | 11.76B |